Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valérie Dutoit

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Cancer Immunology Research|September 13, 2024
PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in GlioblastomaDarel Martinez Bedoya, Eliana Marinari, Suzel Davanture, et al.
Brain : a Journal of Neurology|March 16, 2012
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapyValérie Dutoit, Christel Herold-Mende, Norbert Hilf, et al.
European Urology|April 16, 2013
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)Arnoud J Templeton, Valérie Dutoit, Richard Cathomas, et al.
Immunological Reviews|November 26, 2002
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanomaPedro Romero, Danila Valmori, Mikael J Pittet, et al.
European Journal of Immunology|October 30, 2008
Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replicationDonatella Ciuffreda, Denis Comte, Matthias Cavassini, et al.
Neuro-Oncology|February 13, 2019
Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patientsDenis Migliorini, Valérie Dutoit, Mathilde Allard, et al.
Communications Biology|June 11, 2021
Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cellsLaetitia Seguin, Soline Odouard, Francesca Corlazzoli, et al.
Iscience|January 3, 2022
Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancerNatacha Bordry, Alfredo Addeo, Cyril Jaksic, et al.
Cancer Cell|December 5, 2017
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of GlioblastomaÉrika Cosset, Sten Ilmjärv, Valérie Dutoit, et al.
Cell Death & Disease|September 25, 2023
Identification of a miRNA multi-targeting therapeutic strategy in glioblastomaArthur Bassot, Helena Dragic, Sarah Al Haddad, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Cancer Immunology Research|September 13, 2024
PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in GlioblastomaDarel Martinez Bedoya, Eliana Marinari, Suzel Davanture, et al.
Brain : a Journal of Neurology|March 16, 2012
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapyValérie Dutoit, Christel Herold-Mende, Norbert Hilf, et al.
European Urology|April 16, 2013
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)Arnoud J Templeton, Valérie Dutoit, Richard Cathomas, et al.
Immunological Reviews|November 26, 2002
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanomaPedro Romero, Danila Valmori, Mikael J Pittet, et al.
European Journal of Immunology|October 30, 2008
Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replicationDonatella Ciuffreda, Denis Comte, Matthias Cavassini, et al.
Neuro-Oncology|February 13, 2019
Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patientsDenis Migliorini, Valérie Dutoit, Mathilde Allard, et al.
Communications Biology|June 11, 2021
Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cellsLaetitia Seguin, Soline Odouard, Francesca Corlazzoli, et al.
Iscience|January 3, 2022
Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancerNatacha Bordry, Alfredo Addeo, Cyril Jaksic, et al.
Cancer Cell|December 5, 2017
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of GlioblastomaÉrika Cosset, Sten Ilmjärv, Valérie Dutoit, et al.
Cell Death & Disease|September 25, 2023
Identification of a miRNA multi-targeting therapeutic strategy in glioblastomaArthur Bassot, Helena Dragic, Sarah Al Haddad, et al.
Pageof 7